Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 上海医药 |
|---|---|
| Other Market Stock Code | 601607 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | SH Pharma |
|---|---|
| Stock Code | 02607 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 本集團是中國領先的全國性垂直一體化醫藥公司,業務涵蓋製藥業務、醫藥分銷及供應鏈解決方案、藥品零售,覆蓋醫藥行業價值鏈主要環節。 |
| Listing Date | 2011-05-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海浦東新區張江路92號 |
| Business Address (Hong Kong) | 香港中環皇后大道中15號置地廣場告羅士打大廈8樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.pharm-sh.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 23.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2011-05-12 to 2011-05-12 |
| Global Offering Shares | 664,214,000 shares |
| HK Public Offer Shares (Initial) | 33,210,800 shares (5.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 631,003,200 shares (95.0%) |
| Offer Ratio | ~5.0% |
| Total Shares Post-IPO | 2,656,857,338 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 28.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 15,276,922,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 10.57B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣1,368.3百萬元(權益持有者應享稅後利潤) |
| Period-End Cash Balance | 人民幣6,039.6百萬元 |
| Listing Expenses | ~HK$ 520,000,000 |
| Listing Expenses / Funds Raised | ~3.4% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2008 | 2009 | 2010 |
|---|---|---|---|
| Revenue | 3,214,398 | 4,343,379 | 6,111,948 |
| Cost of sales | -2,932,159 | -4,002,539 | -5,633,842 |
| Gross profit | 282,239 | 340,840 | 478,106 |
| Other income and gains, net | 6,032 | 5,101 | 21,385 |
| Selling and distribution expenses | -89,254 | -109,504 | -165,105 |
| Administrative expenses | -72,250 | -78,429 | -105,740 |
| Net finance costs | -29,517 | -37,288 | -52,592 |
| Share of associates and JVs | 4,403 | 9,163 | 13,760 |
| Profit before tax | 101,653 | 129,883 | 189,814 |
| Income tax expense | -30,207 | -36,290 | -58,099 |
| Profit for the year | 71,446 | 93,593 | 131,715 |
| Profit attributable to owners | 45,903 | 60,915 | 104,807 |
Balance Sheet
| Item | 2008 | 2009 | 2010 |
|---|---|---|---|
| Cash and cash equivalents | 132,460 | 334,934 | 111,792 |
| Trade and bills receivables | 912,814 | 1,338,216 | 2,021,686 |
| Inventories | 469,117 | 706,507 | 1,451,626 |
| Total current assets | 1,649,976 | 2,682,882 | 3,789,557 |
| Total assets | 1,750,823 | 2,789,842 | 3,949,337 |
| Total current liabilities | 1,325,925 | 2,000,847 | 2,949,342 |
| Total liabilities | 1,333,057 | 2,005,395 | 2,953,139 |
| Total equity | 417,766 | 784,447 | 996,198 |
| Equity attributable to owners | 272,110 | 606,113 | 996,198 |
| Interest-bearing borrowings | 338,000 | 946,627 | 1,152,665 |
Cash Flow Statement
| Item | 2010 |
|---|---|
| Net cash from operating activities | -536,660 |
| Net cash from investing activities | -402,018 |
| Net cash from financing activities | 715,536 |
| Net increase in cash | -223,142 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 23.0 |
|---|---|
| First Day Open | HK$ 23.25 |
| First Day Change | -48.22% |
| First Day Volume | 81571700.0 |
| First Day Turnover | 1879790000.0 |
| Use of Proceeds | 1、所得款項凈額約40%(或約5,909百萬港元)預期將用于擴大及加強我們的分銷網絡及整合現有分銷網絡;
2、所得款項凈額約30%(或約4,432百萬港元)預期將用于戰略性收購中國國內及國際醫藥制造業務;
3、所得款項凈額約10%(或約1,477百萬港元)預期將用于產品研發平臺的投資,以進一步加強我們的產品組合及在研產品;
4、所得款項凈額約10%(或約1,477百萬港元)預期將用于信息技術系統及平臺的投資;
5、所得款項凈額剩余約10%(或約1,477百萬港元)預期將用于我們的營運資金需求及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (3)
Joint Bookrunners (4)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | GuoLine Capital Limited | 388,483,800 HKD | — | 2.54% | — | 6 months | 2011-11-20 |
| 2 | 淡马锡控股(私人)有限公司 | 2,330,909,700 HKD | — | 15.26% | — | 6 months | 2011-11-20 |
| 3 | 国浩管理有限公司 | 776,969,900 HKD | — | 5.09% | — | 6 months | 2011-11-20 |
| 4 | 美国辉瑞(香港)有限公司 | 388,483,800 HKD | — | 2.54% | — | 6 months | 2011-11-20 |
| 5 | 中银集团投资有限公司 | 388,483,800 HKD | — | 2.54% | — | 6 months | 2011-11-20 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 呂明方 | — |
| Company Secretary | 韓敏、莫明慧 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 上實集團、上海上實、上藥集團及華源集團為主要股東。緊隨全球發售後(假設超額配售權未獲行使),上實集團持有A股914,958,047股(34.43%)及H股10,000,000股(0.38%);上海上實持有A股914,958,047股(34.43%);上藥集團及華源集團各持有A股752,008,452股(28.30%)。 |
|---|




